Phase 2 N=156 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
NSCLC
Primary: PFS Rate at 18 Months — 51.1; 67.2; 53.5 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Lobular Breast Carcinoma · Gastric Cancer · Triple Negative Breast Cancer
Primary: Percentage of Breast Cancer Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 — 1 Participants
Phase 2 N=40 Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Insomnia
Primary: Change in Daytime Insomnia Symptoms Scale (DISS) — 65.96; 70.34; 69.22; 72.32 units on a scale
Phase 2 N=30 Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women
Tobacco Use Disorder
Primary: Total Cigarettes Per Day — 16.31; 18.36 Cigarettes per day
Phase 2 N=76 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
Phase 2 N=686 Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
Acne Vulgaris
Primary: Absolute Change From Baseline to Week 12 in Lesion Counts. — -29.9; -19.7; -27.9 lesion counts
Phase 2 N=62 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Gene Mutations · Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
Primary: Disease-free Survival (DFS) — .5 proportion of participants
Phase 2 N=21 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
Locally Advanced Thymic Carcinoma · Metastatic Thymic Carcinoma · Recurrent Thymic Carcinoma
Primary: Progression-free Survival — 8; 7 Months
Phase 2 N=5 Erector Spinae Plane Block for Uncomplicated Renal Colic
Renal Colic · Kidney Stone
Primary: Participants Who Received a Second Parenteral Pain Medication in the Emergency Department (ED) — 0 Participants
Phase 2 N=45 MitoQ for Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
Phase 2 N=26 Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Melanoma
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 3; 3; 4 participants
Phase 2 N=177 Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents
Osteoporosis
Primary: Change in Whole Body Bone Mineral Content (BMC) — 20.1; 18.6; 17.3; 20.7 grams — p=0.377
Phase 2 N=59 The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Primary: Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels — 11.1; 12.9 nmol/mL
Phase 2 N=175 ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Primary: Efficacy: Best Objective Response Rate Percent by Treatment Group — 0; 0; 0; 0 Percent (%) of subjects
Phase 2 N=356 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Alzheimer Disease
Primary: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score — 1.02; 0.80; 1.07; 1.15 Score on a scale — p=0.7975